Ipilimumab/pembrolizumabHypophysitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1909卷 / 1期

关键词：

D O I：

10.1007/s40278-022-16593-2

中图分类号：

学科分类号：

摘要：

引用

下载

收藏

页码：306 / 306

相关论文

共 50 条

[31] Ipilimumab/nivolumabHyperthyroidism: case report
Reactions Weekly, 2022, 1916 (1) : 241 - 241
[32] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2021, 1847 (1) : 259 - 259
[33] Ipilimumab/nivolumabMyocarditis: case report
Reactions Weekly, 2022, 1920 (1) : 268 - 268
[34] Ipilimumab/sintilimabAsthma: case report
Reactions Weekly, 2022, 1890 (1) : 143 - 143
[35] Ipilimumab/nivolumabMyocarditis: case report
Reactions Weekly, 2022, 1887 (1) : 397 - 397
[36] Ipilimumab/nivolumabColitis: case report
Reactions Weekly, 2020, 1826 (1) : 185 - 185
[37] Ipilimumab/nivolumabColitis: case report
Reactions Weekly, 2023, 1942 (1) : 157 - 157
[38] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2019, 1748 (1) : 266 - 266
[39] Ipilimumab/nivolumabVitiligo: case report
Reactions Weekly, 2019, 1769 (1) : 262 - 262
[40] Ipilimumab/nivolumabTransaminitis: case report
Reactions Weekly, 2018, 1729 (1) : 152 - 152

← 1 2 3 4 5 →